Evidence map›Paper›PMID 34935641›Full record

ArticleJCI insight2021

Metabolic reprogramming during hyperammonemia targets mitochondrial function and postmitotic senescence.

Avinash Kumar, Nicole Welch, Saurabh Mishra, Annette Bellar, Rafaella Nasciemento Silva, Ling Li, Shashi Shekhar Singh, Mary Sharkoff, Alexis Kerr, Aruna Kumar Chelluboyina and 6 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Ammonia transporter RhBG initiates downstream signaling and functional responses by activating NFκB.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Avinash KumarDepartment of Inflammation & Immunity and.
Nicole WelchDepartment of Inflammation & Immunity and.
Saurabh MishraDepartment of Inflammation & Immunity and.
Annette BellarDepartment of Inflammation & Immunity and.
Rafaella Nasciemento SilvaDepartment of Inflammation & Immunity and.
Ling LiProteomics & Metabolomics Core, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Shashi Shekhar SinghDepartment of Inflammation & Immunity and.
Mary SharkoffDepartment of Inflammation & Immunity and.
Alexis KerrDepartment of Inflammation & Immunity and.
Aruna Kumar ChelluboyinaDepartment of Inflammation & Immunity and.
Jinendiran SekarDepartment of Inflammation & Immunity and.
Amy H AttawayDepartment of Inflammation & Immunity and.
Charles HoppelDepartment of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Belinda WillardProteomics & Metabolomics Core, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Gangarao DavuluriDepartment of Integrated Physiology and Molecular Metabolism, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Srinivasan DasarathyDepartment of Inflammation & Immunity and.
Cleveland Clinic Lerner College of Medicine · USCase Western Reserve University · USCleveland Clinic · USPennington Biomedical Research Center · US

Funding

Project Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI LAURA E. NAGY · 2016 to 2026
$19.6M
VCU-Atlanta Center for the Childhood Liver Disease Research Network (ChiLDReN)U01DK062470 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAUL J. KARPEN · 2005 to 2026
$12.7M
Non Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2M
Immersive Training in GlycosciencesK12HL141952 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASCALL, VINCENT CHARLES, SCHNAAR, RONALD L · 2018 to 2022
$4.8M
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical CenterU01AA026976 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy, David Streem · 2018 to 2026
$3.2M
Novel mechanism based treatment to improve tissue injury in alcoholic hepatitisR01AA028190 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN, NAGY, LAURA E. · 2020 to 2024
$2.8M
Sarcopenia in cirrhosis is mediated by a hyperammonemic stress responseR01DK113196 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN, HATZOGLOU, MARIA · 2018 to 2021
$2.3M
Novel therapeutics for alcoholic hepatitis - Cleveland Translational ComponentU01AA021890 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2012 to 2017
$1.6M
Mechanisms of Malnutrition in Cirrhosis with Portosystemic ShuntingR01GM119174 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2017 to 2020
$1.2M
Mechanisms of HIF1 alpha mediated dysregulated skeletal muscle proteostasis in alcoholic liver diseaseK08AA028794 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI WELCH, NICOLE · 2021 to 2025
$896k
High-End Instrumentation (HEI) Grant Program (S10)S10OD023436 · OD · CLEVELAND CLINIC LERNER COM-CWRU · PI WILLARD, BELINDA BELLE · 2017 to 2017
$873k
Nutritional modulation to minimize resistance exercise induced metabolic deregulations and improve training responsiveness in Chronic Obstructive Pulmonary DiseaseR56HL141744 · NHLBI · TEXAS A&M UNIVERSITY · PI DEUTZ, NICOLAAS E, ENGELEN, MARIELLE PKJ · 2019 to 2019
$757k
NHLBI NIH HHS K12 HL141952NHLBI NIH HHS R56 HL141744NIAAA NIH HHS K08 AA028794NIAAA NIH HHS P50 AA024333NIAAA NIH HHS R01 AA028190NIAAA NIH HHS U01 AA021890NIAAA NIH HHS U01 AA026976NIAMS NIH HHS R21 AR071046NIDDK NIH HHS R01 DK113196NIDDK NIH HHS U01 DK061732NIDDK NIH HHS U01 DK062470NIGMS NIH HHS R01 GM119174NIH HHS S10 OD023436
6 · The paper itself

Abstract

Ammonia is a cytotoxic metabolite with pleiotropic molecular and metabolic effects, including senescence induction. During dysregulated ammonia metabolism, which occurs in chronic diseases, skeletal muscle becomes a major organ for nonhepatocyte ammonia uptake. Muscle ammonia disposal occurs in mitochondria via cataplerosis of critical intermediary metabolite α-ketoglutarate, a senescence-ameliorating molecule. Untargeted and mitochondrially targeted data were analyzed by multiomics approaches. These analyses were validated experimentally to dissect the specific mitochondrial oxidative defects and functional consequences, including senescence. Responses to ammonia lowering in myotubes and in hyperammonemic portacaval anastomosis rat muscle were studied. Whole-cell transcriptomics integrated with whole-cell, mitochondrial, and tissue proteomics showed distinct temporal clusters of responses with enrichment of oxidative dysfunction and senescence-related pathways/proteins during hyperammonemia and after ammonia withdrawal. Functional and metabolic studies showed defects in electron transport chain complexes I, III, and IV; loss of supercomplex assembly; decreased ATP synthesis; increased free radical generation with oxidative modification of proteins/lipids; and senescence-associated molecular phenotype-increased β-galactosidase activity and expression of p16INK, p21, and p53. These perturbations were partially reversed by ammonia lowering. Dysregulated ammonia metabolism caused reversible mitochondrial dysfunction by transcriptional and translational perturbations in multiple pathways with a distinct skeletal muscle senescence-associated molecular phenotype.

Indexed as

AnimalsCellular ReprogrammingHyperammonemiaMitochondriaMitosisProteomicsRatsCell BiologyCellular senescenceHepatologyMitochondriaSkeletal muscle

Identifiers

PMID34935641
PMCPMC8783680
OpenAlexW4200155546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.